Anixa Biosciences, Inc. (ANIX)
NASDAQ: ANIX · IEX Real-Time Price · USD
3.020
+0.010 (0.33%)
Apr 23, 2024, 12:48 PM EDT - Market open

Company Description

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases.

The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.

Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer.

The company is also developing immuno-therapy drugs against cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018.

Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.

Anixa Biosciences, Inc.
Anixa Biosciences logo
Country United States
Founded 1982
IPO Date Jan 1, 1987
Industry Biotechnology
Sector Healthcare
Employees 4
CEO Dr. Amit Kumar Ph.D.

Contact Details

Address:
3150 Almaden Expressway, Suite 250
San Jose, California 95118
United States
Phone 408-708-9808
Website anixa.com

Stock Details

Ticker Symbol ANIX
Exchange NASDAQ
Fiscal Year November - October
Reporting Currency USD
CIK Code 0000715446
CUSIP Number 03528H109
ISIN Number US03528H1095
Employer ID 11-2622630
SIC Code 2834

Key Executives

Name Position
Dr. Amit Kumar Ph.D. Chief Executive Officer, Chairman and Co-Chair of CBAB
Michael J. Catelani CPA, MBA President, Chief Operating Officer, Chief Financial Officer and Corporate Secretary
John Roop Senior Vice President of Engineering
Dr. Pamela D. Garzone Ph.D. Chief Development Officer and Chair Breast Cancer Clinical Advisory Board

Latest SEC Filings

Date Type Title
Mar 22, 2024 8-K Current Report
Mar 12, 2024 10-Q Quarterly Report
Feb 8, 2024 DEF 14A Other definitive proxy statements
Jan 16, 2024 SC 13D/A [Amend] General statement of acquisition of beneficial ownership
Jan 16, 2024 S-8 Securities to be offered to employees in employee benefit plans
Jan 16, 2024 10-K Annual Report
Dec 7, 2023 8-K Current Report
Sep 6, 2023 10-Q Quarterly Report
Jun 14, 2023 10-Q Quarterly Report
Apr 17, 2023 8-K Current Report